Nektar Therapeutics (NASDAQ: NKTR) shares surged 5.22% in pre-market trading on Friday, following the release of its better-than-expected third-quarter financial results. The biopharmaceutical company's earnings report, coupled with recent positive developments in its drug pipeline, has reignited investor interest.

In its Q3 earnings release, Nektar reported a loss of $1.87 per share, significantly outperforming the analyst consensus estimate of a $2.68 loss. This represents a 30% improvement over expectations and a substantial reduction in losses compared to the same period last year. The company's revenue also exceeded projections, reaching $11.79 million against the estimated $10.05 million. Despite a year-over-year decrease, the better-than-anticipated performance has clearly resonated with investors.

Adding to the optimism surrounding Nektar Therapeutics are recent developments in its pipeline and financial position. The FDA granted Fast Track designation for rezpegaldesleukin in severe-to-very-severe alopecia areata, potentially accelerating its path to market. Additionally, the company successfully closed a public stock offering in July, raising $115 million and strengthening its financial position. With cash and investments totaling $270.2 million as of September 30, 2025, Nektar appears well-equipped to continue advancing its promising drug candidates and maintaining its operations, factors that have likely contributed to the significant pre-market stock price increase.